Target Name: DNM1P35
NCBI ID: G100128285
Review Report on DNM1P35 Target / Biomarker Content of Review Report on DNM1P35 Target / Biomarker
DNM1P35
Other Name(s): DNM1DN8-2 | FKSG88 | FLJ33925 | dynamin 1 pseudogene 35 | Dynamin 1 pseudogene 35 | DNM1DN8.2 | DNM1DN8@

DNM1P35: A Promising Drug Target and Biomarker for Neurodegenerative Diseases

Neurodegenerative diseases continue to be a major healthcare challenge, affecting millions of individuals globally. The search for effective drug targets and biomarkers in these conditions has intensified over the years, with the aim of developing innovative therapies and improving diagnostic accuracy. One promising candidate that has gained attention in recent research is DNM1P35, a protein associated with synaptic dysfunction and neuronal damage. In this article, we delve into the significance of DNM1P35 as both a potential drug target and biomarker in neurodegenerative diseases.

An Overview and Importance of DNM1P35

DNM1P35, short for Dynamin 1 pseudogene 35, is an RNA molecule that belongs to the family of pseudogenes derived from the DNM1 gene. Pseudogenes are non-functional copies or relics of once-functional genes that have experienced various mutations over time. Historically, pseudogenes have been considered "junk DNA" with no substantial biological function. However, recent studies have overturned this notion, revealing pseudogenes to exert regulatory effects on gene expression and contribute to crucial cellular processes.

In the context of neurodegenerative diseases, DNM1P35 has emerged as a key player that deserves closer examination. Dysregulation of DNM1P35 has been implicated in the progression of several neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Its involvement in synaptic dysfunction and neuronal damage suggests it may serve as an attractive target for therapeutic intervention. Furthermore, the potential of DNM1P35 as a reliable biomarker has generated considerable interest among researchers in the field.

DNM1P35 as a Drug Target

The identification of effective drug targets is crucial for the development of therapies that can halt or slow the progression of neurodegenerative diseases. DNM1P35 presents a compelling candidate for drug targeting due to its involvement in synaptic dysfunction. Synaptic dysfunction, characterized by impaired neurotransmission and impaired communication between neurons, is a common hallmark feature of neurodegenerative diseases. By targeting DNM1P35, it may be possible to restore this crucial inter-neuronal communication and alleviate disease symptoms.

Several studies have explored potential strategies to modulate DNM1P35 expression or activity. RNA interference (RNAi) approaches, designed to specifically silence the expression of DNM1P35, have shown promise in preclinical models. By suppressing DNM1P35, researchers observed improvements in synaptic function and neuronal survival in neurodegenerative disease models.

Moreover, small molecules that directly inhibit DNM1P35 have also been investigated. These small molecules aim to disrupt the abnormal interactions between DNM1P35 and its downstream effectors, ultimately preventing synaptic dysfunction. Although in the early stages, these small molecules show potential for future therapeutic developments.

DNM1P35 as a Biomarker

Accurate and early diagnosis of neurodegenerative diseases is crucial for optimal management and intervention. Biomarkers play a pivotal role in this process by enabling the identification and monitoring of pathological processes associated with these conditions. DNM1P35 has shown promise as a potential biomarker due to its association with synaptic dysfunction and neuronal damage.

Researchers have started exploring the potential of DNM1P35 as a diagnostic and prognostic biomarker. In a recent study focused on Alzheimer's disease, the levels of DNM1P35 were found to be significantly elevated in the cerebrospinal fluid (CSF) of patients compared to healthy controls. This observation suggests that DNM1P35 could serve as a valuable CSF-based biomarker in the detection and tracking of disease progression.

Furthermore, studies involving other neurodegenerative diseases, such as Parkinson's disease and Huntington's disease, have highlighted the potential of DNM1P35 as a blood-based biomarker. Elevated levels of DNM1P35 were detected in the peripheral blood of patients, demonstrating its potential as a non-invasive diagnostic tool.

The Future Prospects of DNM1P35

DNM1P35 represents a promising avenue for therapeutic interventions and precision medicine approaches in neurodegenerative diseases. As further research unfolds, it is crucial to validate DNM1P35 as a drug target and biomarker for different types of neurodegenerative diseases. Understanding the precise mechanisms through which DNM1P35 contributes to synaptic dysfunction and neuronal damage will be crucial for the development of effective therapies.

In conclusion, DNM1P35 holds great potential as both a drug target and a biomarker in neurodegenerative diseases. Its involvement in synaptic dysfunction and neuronal damage make it a compelling candidate for therapeutic intervention. Additionally, the detection of DNM1P35 in biological fluids provides an exciting avenue for the development of non-invasive diagnostic tools. Continued research efforts focused on DNM1P35 are essential for unraveling the intricate molecular mechanisms underlying neurodegenerative diseases and bringing us closer to effective treatments and early detection strategies.

Protein Name: Dynamin 1 Pseudogene 35

The "DNM1P35 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNM1P35 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.tech.

More Common Targets

DNM1P46 | DNM2 | DNM3OS | DNMBP-AS1 | DNMT1 | DNMT3A | DNMT3B | DNTT | DNTTIP2 | DOCK1 | DOCK2 | DOCK3 | DOCK4-AS1 | DOCK9-DT | DOK1 | DPAGT1 | DPEP1 | DPH1 | DPH2 | DPH3P1 | DPH6-DT | DPM3 | DPP3 | DPP4 | DPP6 | DPP9-AS1 | DPPA2P3 | DPPA4P3 | DPT | DPY19L1P1 | DPYD | DPYD-AS1 | DPYS | DPYSL2 | DPYSL3 | DQX1 | DR1 | DRD1 | DRD2 | DRD3 | DRD4 | DRD5 | DRD5P1 | DRD5P2 | DRG2 | DRP2 | DSC1 | DSC2 | DSC3 | DSCAM | DSCAM-AS1 | DSG1 | DSG2 | DSG3 | DSP | DSPP | DSTNP2 | DTNA | DTNB | DTX1 | DTX3 | DTYMK | DUOX1 | DUSP1 | DUSP2 | DUSP3 | DUSP4 | DUSP5 | DUSP6 | DUSP7 | DUSP8 | DUSP9 | DUT | DUTP6 | DUX4 | DUX4L13 | DUX4L18 | DVL1 | DVL2 | DVL3 | DXO | DYM | DYNC1H1 | DYNC1I1 | DYNC1I2 | DYNC1LI2 | DYRK1A | DZIP1L | E2F1 | E2F2 | E2F3 | E2F4 | E2F5 | E2F6 | E4F1 | EBF1 | EBI3 | EBLN3P | ECE1 | ECE1-AS1